NASDAQ:CRBU Caribou Biosciences (CRBU) Stock Price, News & Analysis $1.99 -0.01 (-0.50%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$1.96 -0.03 (-1.51%) As of 07:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Caribou Biosciences Stock (NASDAQ:CRBU) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Caribou Biosciences alerts:Sign Up Key Stats Today's Range$1.88▼$2.0250-Day Range$1.72▼$2.3652-Week Range$0.96▼$3.54Volume1.37 million shsAverage Volume1.61 million shsMarket Capitalization$197.37 millionP/E RatioN/ADividend YieldN/APrice Target$8.67Consensus RatingModerate Buy Company Overview Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis. Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology. The company holds licenses to foundational CRISPR intellectual property from the University of California, enabling continuous innovation in genome engineering. Since completing its initial public offering in August 2021, Caribou has focused on progressing its clinical pipeline and expanding manufacturing capabilities to support its growing roster of investigational therapies. Caribou’s leadership team combines deep expertise in molecular biology, clinical development and manufacturing scale-up, supported by an advisory board that includes leading figures in biotechnology and medicine. The company has established strategic collaborations with pharmaceutical and academic partners to advance its research programs and accelerate clinical translation. Caribou continues to conduct trials across multiple regions, aiming to bring its next-generation cell therapies and in vivo gene-editing treatments to patients worldwide.AI Generated. May Contain Errors. Read More Caribou Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreCRBU MarketRank™: Caribou Biosciences scored higher than 49% of companies evaluated by MarketBeat, and ranked 538th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingCaribou Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCaribou Biosciences has a consensus price target of $8.67, representing about 335.5% upside from its current price of $1.99.Amount of Analyst CoverageCaribou Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Caribou Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Caribou Biosciences are expected to decrease in the coming year, from ($1.21) to ($1.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Caribou Biosciences is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Caribou Biosciences is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCaribou Biosciences has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.85% of the float of Caribou Biosciences has been sold short.Short Interest Ratio / Days to CoverCaribou Biosciences has a short interest ratio ("days to cover") of 4.35.Change versus previous monthShort interest in Caribou Biosciences has recently increased by 5.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCaribou Biosciences does not currently pay a dividend.Dividend GrowthCaribou Biosciences does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.38 News SentimentCaribou Biosciences has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Caribou Biosciences this week, compared to 3 articles on an average week.Search Interest10 people have searched for CRBU on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.MarketBeat Follows2 people have added Caribou Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Caribou Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $35,454.00 in company stock.Percentage Held by Insiders8.54% of the stock of Caribou Biosciences is held by insiders.Percentage Held by Institutions77.51% of the stock of Caribou Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Caribou Biosciences' insider trading history. Receive CRBU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRBU Stock News HeadlinesCaribou Biosciences Details CAR T Pipeline, Pivotal Trial Plans and Cash Runway3 hours ago | americanbankingnews.comCaribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 15, 2026 | seekingalpha.comA 17-year investing experiment investigated in DublinPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 22 at 1:00 AM | Porter & Company (Ad)Bank of America Securities Remains a Buy on Caribou Biosciences (CRBU)May 14, 2026 | theglobeandmail.comCaribou Biosciences (CRBU) price target increased by 38.57% to 12.37May 14, 2026 | msn.comIndustry Analysts Just Made A Massive Upgrade To Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenue ForecastsMay 13, 2026 | finance.yahoo.comCaribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor ConferenceMay 13, 2026 | globenewswire.comCaribou Biosciences, Inc. Announces Acceptance of Two Oral Presentations at the 2026 European Hematology Association Annual MeetingMay 12, 2026 | quiverquant.comQSee More Headlines CRBU Stock Analysis - Frequently Asked Questions How have CRBU shares performed this year? Caribou Biosciences' stock was trading at $1.59 at the start of the year. Since then, CRBU stock has increased by 25.2% and is now trading at $1.99. How were Caribou Biosciences' earnings last quarter? Caribou Biosciences, Inc. (NASDAQ:CRBU) announced its quarterly earnings data on Thursday, May, 7th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.07. The business earned $2.40 million during the quarter, compared to the consensus estimate of $2.21 million. Caribou Biosciences had a negative trailing twelve-month return on equity of 84.17% and a negative net margin of 1,189.14%. When did Caribou Biosciences IPO? Caribou Biosciences (CRBU) raised $285 million in an initial public offering (IPO) on Wednesday, July 21st 2021. The company issued 19,000,000 shares at a price of $14.00-$16.00 per share. Who are Caribou Biosciences' major shareholders? Caribou Biosciences' top institutional shareholders include Renaissance Technologies LLC (2.61%), Bank of America Corp DE (1.31%), Dimensional Fund Advisors LP (0.68%) and OMERS ADMINISTRATION Corp (0.12%). Insiders that own company stock include Rachel E Haurwitz, Barbara G Mcclung, Ruhi Ahmad Khan, Timothy P Kelly, Tina M Albertson and Sriram Ryali. View institutional ownership trends. How do I buy shares of Caribou Biosciences? Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Caribou Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Caribou Biosciences investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/07/2026Today5/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CRBU's financial health is in the Green zone, according to TradeSmith. CRBU has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRBU CIK1619856 Webcariboubio.com Phone510-982-6030FaxN/AEmployees100Year Founded2012Price Target and Rating Average Price Target for Caribou Biosciences$8.67 High Price Target$11.00 Low Price Target$7.00 Potential Upside/Downside+335.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$148.12 million Net Margins-1,189.14% Pretax Margin-1,194.05% Return on Equity-84.17% Return on Assets-60.51% Debt Debt-to-Equity RatioN/A Current Ratio6.22 Quick Ratio6.22 Sales & Book Value Annual Sales$11.20 million Price / Sales17.62 Cash FlowN/A Price / Cash FlowN/A Book Value$1.03 per share Price / Book1.93Miscellaneous Outstanding Shares99,181,000Free Float90,711,000Market Cap$197.37 million OptionableOptionable Beta2.27 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:CRBU) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredSMX Could Be One of the Most Interesting Small Caps Right NowSMX (Security Matters) is developing molecular-level markers that embed digital identities directly into plast...Smallcaps Daily | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?On July 17th, the House passed the GENIUS Act - and at least one prominent Trump ally is raising alarms. Rep. ...Goldco Direct, LLC | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
